Ningbo First Hospital

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Source

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Source

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Source

• Recruiting

  Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

  NCT06375005· Phase 2· Source

• Recruiting

  IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

  NCT06647862· Phase 3· Source

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Source

• Not yet recruiting

  Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

  NCT05970627· Phase 2· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  NCT05869903· Phase 3· Source

• Recruiting

  Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

  NCT05729646· Phase 2· Source

• Active, not recruiting

  Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

  NCT05715931· Phase 2· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Recruiting

  CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

  NCT05659628· Phase 1· Source

• Active, not recruiting

  Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT05479994· Phase 2· Source

• Active, not recruiting

  Healthy Weight Management Project for Overweight and Obesity Children

  NCT05482191· Source

• Active, not recruiting

  Optimizing Intervention Effects in Children and Adolescents

  NCT05482165· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Source

• Recruiting

  PROfiling Based Endometrial Cancer Adjuvant Therapy

  NCT05179447· Source

• Recruiting

  Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

  NCT04974346· Phase 3· Source

• Active, not recruiting

  A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

  NCT05058040· Phase 4· Source

• Recruiting

  Abbott Vascular Medical Device Registry

  NCT04573660· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Source

• Recruiting

  Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

  NCT04937283· Source

• Active, not recruiting

  Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

  NCT03967977· Phase 3· Source

• Active, not recruiting

  A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

  NCT03706365· Phase 2/3· Source

• Active, not recruiting

  Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

  NCT02455141· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity6 recruiting
• Type 2 diabetes3 recruiting
• Gastric and esophageal cancer2 recruiting
• Bladder cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.

  NCT06849843· Phase 2· Source

• Completed

  A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT06649045· Phase 3· Source

• Completed

  Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

  NCT06492031· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

  NCT05362058· Phase 3· Source

• Completed

  A Study of Vedolizumab in Adults in Real-World Practice

  NCT04872491· Source

• Completed

  A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04939142· Phase 3· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Source

• Completed

  Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

  NCT04736199· Phase 3· Source

• Completed

  Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

  NCT04643470· Phase 2· Source

• Completed

  A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

  NCT04238715· Phase 2· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622· Phase 3· Source